Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR X Ma, L Long, S Moon, BJS Adamson, SS Baxi Medrxiv, 2020.03. 16.20037143, 2020 | 281 | 2020 |
Discordant SARS-CoV-2 PCR and rapid antigen test results when infectious: a December 2021 occupational case series B Adamson, R Sikka, AL Wyllie, P Premsrirut Medrxiv, 2022.01. 04.22268770, 2022 | 71 | 2022 |
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. BJS Adamson, AB Cohen, M Estevez, K Magee, E Williams, CP Gross, ... Journal of Clinical Oncology 37 (18_suppl), LBA1-LBA1, 2019 | 53 | 2019 |
Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer E Feld, J Harton, NJ Meropol, BJS Adamson, A Cohen, RB Parikh, ... European urology 76 (4), 524-532, 2019 | 47 | 2019 |
Machine learning methods in health economics and outcomes research—the PALISADE checklist: a good practices report of an ISPOR task force WV Padula, N Kreif, DJ Vanness, B Adamson, JD Rueda, F Felizzi, ... Value in health 25 (7), 1063-1080, 2022 | 42 | 2022 |
Enhancing diversity in the public health research workforce: the research and mentorship program for future HIV vaccine scientists CJ Sopher, BJS Adamson, MP Andrasik, DM Flood, SF Wakefield, ... American Journal of Public Health 105 (4), 823-830, 2015 | 42 | 2015 |
Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real‐world practice RB Parikh, MD Galsky, B Gyawali, F Riaz, TL Kaufmann, AB Cohen, ... The Oncologist 24 (6), e397-e399, 2019 | 41 | 2019 |
Adoption of immune checkpoint inhibitors and patterns of care at the end of life F Riaz, G Gan, F Li, AJ Davidoff, KB Adelson, CJ Presley, BJ Adamson, ... JCO Oncology Practice 16 (11), e1355-e1370, 2020 | 29 | 2020 |
The cost-effectiveness of financial incentives for viral suppression: HPTN 065 study B Adamson, W El-Sadr, D Dimitrov, T Gamble, G Beauchamp, JJ Carlson, ... Value in health 22 (2), 194-202, 2019 | 27 | 2019 |
Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer RB Parikh, BJS Adamson, S Khozin, MD Galsky, SS Baxi, A Cohen, ... JAMA 322 (12), 1209-1211, 2019 | 22 | 2019 |
ACA Medicaid expansion association with racial disparity reductions in timely cancer treatment. BJS Adamson, AB Cohen, CP Gross, M Estévez, K Magee, E Williams, ... American Journal of Managed Care 27 (7), 2021 | 21 | 2021 |
The potential cost-effectiveness of pre-exposure prophylaxis combined with HIV vaccines in the United States BJS Adamson, JJ Carlson, JG Kublin, LP Garrison Jr Vaccines 5 (2), 13, 2017 | 21 | 2017 |
Programmed death-ligand 1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous NSCLC DB Doroshow, W Wei, S Gupta, J Zugazagoitia, C Robbins, B Adamson, ... Journal of Thoracic Oncology 16 (12), 2139-2143, 2021 | 19 | 2021 |
The potential cost-effectiveness of HIV vaccines: A systematic review B Adamson, D Dimitrov, B Devine, R Barnabas PharmacoEconomics-open 1, 1-12, 2017 | 19 | 2017 |
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study S de Montigny, BJS Adamson, BR Mâsse, LP Garrison Jr, JG Kublin, ... Scientific Reports 8 (1), 6066, 2018 | 18 | 2018 |
The impact of ACA and Medicaid expansion on progress toward UNAIDS 90-90-90 goals B Adamson, L Lipira, AB Katz Current HIV/AIDS Reports 16, 105-112, 2019 | 17 | 2019 |
Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020: 2020.03. 16.20037143 X Ma, L Long, S Moon, BJS Adamson, SS Baxi Preprint, not peer-reviewed, 2022 | 16 | 2022 |
Approach to machine learning for extraction of real-world data variables from electronic health records B Adamson, M Waskom, A Blarre, J Kelly, K Krismer, S Nemeth, J Gippetti, ... Frontiers in Pharmacology 14, 1180962, 2023 | 14 | 2023 |
Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv, 2020.03. 16.20037143 X Ma, L Long, S Moon, BJS Adamson, SS Baxi Accessed 10th Feb, 2022 | 13 | 2022 |
Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa C Selinger, A Bershteyn, DT Dimitrov, BJS Adamson, P Revill, TB Hallett, ... Vaccine 37 (16), 2258-2267, 2019 | 13 | 2019 |